Article Information
History
- February 9, 2021.
Article Versions
- Version 1 (February 5, 2021 - 11:50).
- Version 2 (February 8, 2021 - 09:48).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Hannah Higgins, MPhil1,
- Amy M. Mason, PhD1,
- Susanna C. Larsson, PhD2,3,
- Dipender Gill, BMBCh PhD4,5,6,7,8,
- Claudia Langenberg, MD PhD9 and
- Stephen Burgess, PhD1,10,*
- 1Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- 2Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
- 3Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 4Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
- 5Centre for Pharmacology and Therapeutics, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
- 6Department of Genetics, Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK
- 7Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George’s, University of London, London, UK
- 8Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George’s University Hospitals NHS Foundation Trust, London, UK
- 9MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
- 10Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK
- ↵*Correspondence to:
Stephen Burgess. Email: sb452{at}medschl.cam.ac.uk.
Posted February 09, 2021.
Estimating the Population Benefits of Blood Pressure Lowering: A Wide-Angled Mendelian Randomization Study in UK Biobank
